|
Published by: Espicom Healthcare Intelligence
Published: Jun. 26, 2007 - 160 Pages
Table of Contents
- Foreword
- Introduction
- Background to the Market
- Geography
- Political Overview
- Economic Overview
- Demographics
- Demographic indicators
- The UK Healthcare System
- Organisation
- Primary Care Trusts
- Healthcare expenditure
- Hospital beds
- Medical personnel
- The UK Generics Market
- In Context: the UK Pharmaceutical Market
- Market Structure
- Reimbursement
- Pricing: the PPRS
- Unbranded Generic Pricing
- 2005 generics reimbursement scheme
- Generic price reductions for four major drugs
- DOH Holds consultations regarding branded generics in the PPRS
- Regulation of Pharmaceuticals
- Generic regulation
- Intellectual Property
- Supplementary Protection Certificates
- Prescription Medicines Market
- England
- Generic Market Size
- Generic Prescribing
- Scotland
- Wales
- Outlook for Future Growth
- Investigations into price fixing
- Department of Health
- Ranbaxy and Merck settle DOH claims
- Serious Fraud Office
- Overview of the Domestic Industry
- Total Turnover
- UK Turnover
- Operating Profit
- Net Profit
- Employees
- Sales per Employee
- Leading Players in the Market
- Actavis UK Ltd
- Actavis worldwide
- Actavis in the UK
- Products on the UK market
- Financial indicators
- Arrow Generics Ltd
- Products on the UK market
- Financial indicators
- Bristol Laboratories
- Products on the UK Market
- Financial indicators
- Crescent Pharma
- Products on the UK market
- Financial indicators
- Dr Reddy's Laboratories (UK) Ltd
- Dr Reddy's worldwide
- UK operations
- Financial indicators
- Focus Pharmaceuticals
- Products in the UK
- Financial Indicators
- Generics (UK) Ltd
- Merck Generics worldwide
- UK Operations
- Products in the UK market
- Financial indicators
- Genus Pharmaceuticals
- Products
- Financial indicators
- Goldshield Pharmaceuticals Ltd
- Goldshield Group
- Products
- Financial indicators
- Kent Pharmaceuticals
- Products
- Financial indicators
- Perrigo UK Ltd
- Products
- Financial indicators
- Pliva Pharma Ltd
- Pliva worldwide
- Pliva in the UK
- Financial indicators
- Ranbaxy (UK) Ltd
- Ranbaxy worldwide
- Ranbaxy in the UK
- Financial indicators
- ratiopharm UK
- ratiopharm worldwide
- ratiopharm in the UK
- Financial indicators
- Rosemont Pharmaceuticals
- Products
- Financial indicators
- Sandoz
- Sandoz worldwide
- Sandoz in the UK
- Products
- Financial indicators
- Teva UK
- Teva worldwide
- Teva in the UK
- Financial indicators
- Winthrop Pharmaceuticals
- Winthrop worldwide
- Winthrop in the UK
- Products
- Financial indicators
- Wockhardt UK Ltd
- Wockhardt worldwide
- Wockhardt in the UK
- Products
- Financial indicators
- Marketing Authorisations in 2006
- Trading Companies
- Wholesaling
- AAH Pharmaceuticals Ltd
- Alliance Boots (formerly Alliance Unichem)
- Exclusive Distribution Deal with Pfizer
- Mawdsleys
- Phoenix Healthcare Distribution Ltd
- Retailing
- Major Pharmacy Chains
- Alliance Boots
- Lloyds Pharmacy
- Superdrug
- Appendix 1: Analysis of Leading Patent-Expired Drugs
- Amisulpride
- Risperidone
- Ramipril
- Glimepiride
- Ondansetron
- Sumatriptan
- Amlodipine
- Citalopram
- Fluconazole
- Gabapentin
- Lamotrigine
- Meloxicam
- Meloxicam
- Sertraline
- Tamsulosin
- Terbinafine
- Appendix 2: Rising Use of Generics in the UK Statins Market
- Market Developments
- Atorvastatin
- Fluvastatin
- Pravastatin
- Rosuvastatin
- Simvastatin
- Appendix 3: Generics in the UK PPI Market
- Esomeprazole
- Lansoprazole
- Omeprazole
- Pantoprazole
- Rabeprazole sodium
- Appendix 4: Sources
- Espicom Sources
- UK Government Sources
- Industry Sources
- Appendix 5: DIRECTORY
- Regulators
- Trade Bodies
- Manufacturers
AbstractThe £2.4 billion UK generics market is one of the world's largest in terms of both size and generic penetration. In 2005 over 59% of prescriptions were dispensed as generics, accounting for 26% of the market value. But fierce competition and price pressure are turning up the heat. How will the market continue to grow?
Key areas addressed:
- 5-Year market forecast to 2012 for value
- The generics market in context of the whole pharmaceutical industry
- Pricing issues and reimbursement
- Political, legal and economic assessment
- Insightful review of 18 major domestic and foreign players in the market
- Detailed listing of 18 leading products including prescription data, price comparisons and marketing authorisations
- Focus on developing generic markets for statins and proton pump inhibitors
The UK generics market has proved a difficult operating environment in recent years. Many established suppliers have experienced declining sales and profitability, due to a number of factors. On the one hand, the market is relatively easy to enter, leading to rapid and fierce price competition for major drugs. On the other, the UK government keeps a close watch on generic drug pricing, and has proved willing to reduce prices for a number of products in recent years.
As in the wider global market, there are signs of ongoing industry consolidation. Teva and IVAX both have a strong presence in the UK, making Teva the clear market leader since its 2006 purchase of IVAX. One new development is the growing arrival of US companies in the market with control of Pliva going to Barr Laboratories in 2006, and Generics (UK) set to become part of Mylan in 2007. There are no major UK-owned generic manufacturers.
But who are the leading players and what are their strengths? What barriers to market entry exist? What marketing authorisations have recently been issued, and to whom? What will be the operating and regulatory environment for companies? The answers to these and many other questions can be found in this 160-page management report Opportunities and Challenges for Generic Drugs in the UK.
OPPORTUNITIES AND CHALLENGES FOR
GENERIC DRUGS IN THE UK
Facts, figures, and analysis of
companies, products and issues.
All you need to know for an informed business judgement!
Get Full Details About This Report >>
|
